MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'cell therapeutics'. Sat, 03 Sep 2011 02:38:09 +0100 http://www.medworm.com/index.php?rid=4411724&cid=t_131159_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FpVHziCcV3_E%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is our regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that Angelini Labopharm named Mary Anne Heino as president. She was formerly senior vp of sales and marketing at Labopharm, which last spring formed a joint venture with Angelini to commercialize an antidepressant. Before joining Labopharm, Heino wa... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4411724 Fri, 28 Jan 2011 13:16:55 +0100 4411724 http://www.medworm.com/index.php?rid=3973117&cid=t_131159_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fb2h0UB6N-As%2F Rise and shine, everyone. Another day is upon us. But this is a good thing. As one of our favorite sages, the Morning Mayor, used to say: Every brand new day should be unwrapped like a precious gift. While you tug on the ribbon, we will brew the mandatory cup of stimulation and poke around for interesting items. Here, in fact, are a few to help you get started. Have a good one and stay in touch… Roche Rules Out Merging R&D With Genentech (Reuters) Abbott To Close Canadian Baby Formula Plant (Brockville Recorder & Times) China’s BGI And Merck Form Alliance (Bio-IT World) Abbott Fights To Keep Meridia Diet Pill On The Market (Reuters) K-V Pharmaceutical Secures A $20M Loan (Fox Business) Genentech CEO Resigns From Dendreon Board (Xconomy) Cell Therapeutics Appeals FDA R... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3973117 Wed, 15 Sep 2010 11:51:18 +0100 3973117 http://www.medworm.com/index.php?rid=3476081&cid=t_131159_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FUS9QAvJBpCU%2F And so another work week will soon draw to a close. What do your weekend plans call for? A walk in the park? A long, cozy nap? Tending to chores? Schlepping your own short people from place to place? Whatever you do, we hope you have a nice time. Meanwhile, there is today to wrap up. So here are a few items of note. See you soon… Genzyme Patients Feel Betrayed By Shortages (The New York Times) Pfizer Is Voted Best Employer In Czech Republic (Prague Daily Monitor) J&J Axes Execs In India (Economic Times) Cell Therapeutics Cuts 36 Employees (Xconomy) Rexahn Stumbles Over MDD Drug (Montgomery Gazette) photo thx to tipiro on Flickr creative commons (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3476081 Fri, 16 Apr 2010 11:38:17 +0100 3476081 http://www.medworm.com/index.php?rid=3338404&cid=t_131159_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F03%2F05%2Fgog-says-continuation-of-pivotal-opaxio-maintenance-therapy-trial-gog-212-remains-high-priority%2F Gynecologic Oncology Group (GOG) Notifies CTI That Continuation of GOG-212 Pivotal Trial of OPAXIO Maintenance Therapy in Front Line Ovarian Cancer Remains High Priority.  GOG-218 Bevacizumab Results Do Not Influence Importance of GOG-212 Cell Therapeutics, Inc. (“CTI”) announced today that the company received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3338404 Sat, 06 Mar 2010 02:48:42 +0100 3338404 http://www.medworm.com/index.php?rid=3262894&cid=t_131159_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FiRm4YOCZj24%2F Earlier this week, shares in Cell Therapeutics plunged when FDA documents revealed serious concerns about the safety and effectiveness of the biotech’s pixantrone med for non-Hodgkin’s lymphoma. The documents were posted online in advance of a meeting that was scheduled for today, although postponed due to the latest snowstorm. The FDA noted the drug was associated with potentially fatal cardiac side effects, including heart failure, and the agency questioned the strength of a Phase III trial, which enrolled far fewer patients than originally planned - 140 instead of 320 (click here and go to briefing documents). Yet the company had continually maintained it was operating under a Special Protocol Assessment, or SPA. What is an SPA? This is an agreement between a drugmaker and t... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3262894 Wed, 10 Feb 2010 16:08:55 +0100 3262894 http://www.medworm.com/index.php?rid=3259243&cid=t_131159_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FiRm4YOCZj24%2F Earlier this week, shares in Cell Therapeutics plunged when FDA documents revealed serious concerns about the safety and effectiveness of the biotech’s pixantrone med for non-Hodgkin’s lymphoma. The documents were posted online in advance of a meeting that was scheduled for today, although postponed due to the latest snowstorm. The FDA noted the drug was associated with potentially fatal cardiac side effects, including heart failure, and the agency questioned the strength of a Phase III trial, which enrolled far fewer patients than originally planned - 140 instead of 320 (click here and go to briefing documents). Yet the company had continually maintained it was operating under a Special Protocol Assessment, or SPA. What is an SPA? This is an agreement between a drugmaker and t... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3259243 Wed, 10 Feb 2010 16:08:55 +0100 3259243 http://www.medworm.com/index.php?rid=3008400&cid=t_131159_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FdhdtK3ob5sQ%2F This may add a whole new wrinkle to whistleblower lawsuits. A federal appeals court ruled that Cell Therapeutics can pursue a claim for nearly $23 million against a former consultant, the Associated Press reports. And the 9th U.S. Circuit Court of Appeals ruling creates a new interpretation of law surrounding fraud cases brought on behalf of the government (the ruling). The case concerns Trisenox, a leukemia drug developed by Cell Therapeutics, which claims it marketed the med off-label on the advice of a consultant, formerly known as Documedics Acquisition and now called Lash Group, the AP writes. As a result, docs billed Medicare for unapproved uses. After a former employee filed a whistleblower lawsuit, Cell Therapeutics agreed to settle $10.5 million without admitting liability. Cell T... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3008400 Thu, 19 Nov 2009 12:55:27 +0100 3008400 http://www.medworm.com/index.php?rid=2110588&cid=t_131159_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2009%2F01%2F1-million-ceo-for-27-million.html From the Seattle Times comes a story of how top executives in biotechnology may be paid for lack of performance,Even in a disastrous year on Wall Street, Cell Therapeutics stood out in 2008. Its stock price dropped 99.25 percent.But the cash-strapped Seattle biotech's top five executives had reason to celebrate Dec. 31: That day they were awarded year-end bonuses totaling more than $1 million.Chief Executive James Bianco, who has run the company since founding it in 1992, was awarded a $487,500 bonus to supplement his $650,000 salary and other perks.Cell Therapeutics' eight board members, who include Bianco, chose to pay 75 percent of the bonuses in cash, and will decide March 1 whether 'the company is sufficiently liquid to pay the remaining amount.' In other words, the board wasn't certa... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=2110588 Fri, 16 Jan 2009 20:37:00 +0100 2110588 http://www.medworm.com/index.php?rid=1416444&cid=t_131159_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F282053758%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs being announced each month. Despite downsizing, there is movement. Here are some of the latest changes. Recognize anyone? AssureRx hired Al Lucas as vp of sales and marketing; Oragenics added Marc Siegel and Kevin Sills to its board; Noven Pharmaceuticals hired Peter Brandt as ceo and president; Hyperion Therapeutics hired Bruce Scharschmidt as chief medical officer; Cephalon hired Jerry Pappert as exec vp and general counsel; MedThink Communications hired Steve Palmisan... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1416444 Fri, 02 May 2008 11:42:29 +0100 1416444 http://www.medworm.com/index.php?rid=1332728&cid=t_131159_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F259597895%2F We are particularly happy, especially after our difficulties yesterday. You may have noticed sporadic posting, which was due to a burst pipe valve in the basement of the Pharmalot headquarters, a disruption assuaged only by our on-call Pharmalot maintenance crew. The problem has been solved, although we look forward to a respite. Nonetheless, there is much to do, especially as the American College of Cardiology conference kicks off and we prepare for a speaking engagement of our own. So grab that cup of stimulation and polish off the week with us… Drug-Coated Stents No Riskier Than Others: Study (Dow Jones) Some Biotechs Race To Develop Biosimilars (Bloomberg News) J&J Foot Gel Poses Cancer Risk (Yahoo/Reuters) Takeda Scraps Development Of Cholesterol Pill (Bloomberg News) Wyeth... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1332728 Fri, 28 Mar 2008 11:10:55 +0100 1332728 http://www.medworm.com/index.php?rid=1237791&cid=t_131159_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F236520530%2F That’s right. The US Attorney in Seattle has appealed a ruling made two months ago by a federal judge, who determined that former Cell Therapeutics sales rep Jim Marchese was entitled to $1.6 million, or 15 percent of a $10.5 million fine that was paid by his former employer for off-label promotion of a cancer drug. The notice of appeal to the US District Court of Appeals for the Ninth Circuit was filed earlier this month in federal court in Seattle. For those who don’t recall, the federal government relied on Marchese to make its case but, in an usual twist, turned around and accused him of masterminding the complex off-label scheme, and argued he didn’t deserve a dime, rather than the customary 15 percent to 25 percent that a whistleblower would typically receive. The ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1237791 Sun, 17 Feb 2008 19:16:31 +0100 1237791 http://www.medworm.com/index.php?rid=1096755&cid=t_131159_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F200625829%2F You read it here first. Jim Marchese has won his battle with the federal government. The former Cell Therapeutics sales rep was seeking a share of a $10.5 million fine his former employer paid earlier this year for fraudulently marketing a cancer drug and bilking Medicare out of millions of dollars. But the federal government recently turned around and accused him of masterminding a complex off-label scheme and argued Marchese didn’t deserve a dime. The US Attorney in Seattle also claimed Marchese destroyed or failed to turn over evidence when he first blew the whistle on CTI. Marchese denied it all. Today, though, US federal judge Marsha Pechman issued a 14-page ruling (this is it) in which she decided that Marchese is, indeed, entitled to a 15 percent share of the proceeds and tha... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1096755 Sat, 15 Dec 2007 12:51:48 +0100 1096755 http://www.medworm.com/index.php?rid=1030260&cid=t_131159_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F185289003%2F You may recall that last month we wrote about a former sales rep at Cell Therapeutics named Jim Marchese who, after losing his job five years ago, met with the Justice Department to say the drugmaker had fraudulently marketed a cancer drug and bilked Medicare out of millions of dollars. And the federal government joined him in suing the drugmaker, which earlier this year forked over $10.5 million in fines. More recently, however, the government turned around and accused Marchese of being the brains behind the fraud - “the planner and initiater” of the scam, according to documents filed in US District Court in Seattle. The US Attorney maintains Marchese also destroyed or failed to turn over evidence when he first blew the whistle on CTI. And so while whisteblowers are generally ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1030260 Thu, 15 Nov 2007 16:20:50 +0100 1030260 http://www.medworm.com/index.php?rid=977428&cid=t_131159_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F174834426%2F This is the kind of tale that may give some pause before they decide they have a whistle to blow. After Jim Marchese left his job as a sales rep for Cell Therapeutics several years ago, he met with the Justice Department to say the drugmaker had fraudulently marketed a cancer drug and bilked Medicare out of millions of dollars, The New York Times reports. And the government joined him in suing the drugmaker. In April, Cell Therapeutics agreed to pay $10.5 million to the government to settle the charges. And Marchese was in line to receive as much as a quarter of that sum, or $2.8 million, as his reward for blowing the whistle. But the Times writes that the Justice Department had a change of heart and is asking a federal judge to award him nothing. The government now contends that Marchese,... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=977428 Thu, 25 Oct 2007 13:01:21 +0100 977428 http://www.medworm.com/index.php?rid=904631&cid=t_131159_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F161496556%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. Here are some of the latest moves… Lilly names Lauren Marangell as a Distinguished Scholar; Cardinal Health named ceo R. Kerry Clark as chairman; Shire appointed Sylvie Gregoire as prez, human genetic therapies biz; Cell Therapeutics adds Richard Love to its board; MacroGenics named Jeff Buchalter as chairman; Stiefel Labs appointed Lodewijk de Vink, to its board; Keryx Biopharmaceuticals named Mike Tarnok to its board; Gen-Probe named John Martin to its board; CG Therapeutics appointed Chris Henney ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=904631 Wed, 26 Sep 2007 11:29:25 +0100 904631 http://www.medworm.com/index.php?rid=774271&cid=t_131159_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F139924800%2F More companies and cancer patients are imploring the FDA to approve experimental cancer meds, even when current approval standards aren’t met. Pharmacyclics recently refiled an application for its cancer drug, despite agency refusal to review it in February. Cell Therapeutics argues its lung-cancer drug is being delayed by the FDA’s insistence it conduct another trial. And prostate-cancer patients and shareholders have protested the FDA’s refusal in May to approve Provenge vaccine by Dendreon. Yet another example is Antigenics, which is pushing a subgroup analysis, something the FDA resists, as The Wall Street Journal (subscription required) writes this morning. The issue, however, is becoming more heated as patients - and, of course, investors - argue that meds for life-... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=774271 Thu, 02 Aug 2007 12:22:58 +0100 774271 http://www.medworm.com/index.php?rid=728715&cid=t_131159_150_f&fid=35781&url=http%3A%2F%2Fwww.qdinformation.com%2Fqdisblog%2F2007%2F05%2F21%2Fcell-therapeutics-to-pay-105-million%2F Seems my old company is now paying $10.5 million to resolve claims that they were promoting Trisenox for uses that were not approved. Cell Therapeutics to pay $10.5 million: I always thought they were leaving them selves open for this sort of problems back when I was working for them given the huge amount of off-label use. When a huge portion of your drug is being used for diseases it isn’t approved for, you are going to raise some eyebrows. I should note that “Cell Therapeutics does not admit any wrongdoing in the matter”. And we all know what that really means. Technorati Tags: CEll THerapeutics Copyright © 2007 QDIS Blog. This Feed is for personal non-commercial use only. If you are not reading this material in your news aggregator, the site you are looking at is ... QDIS Blog blogs http://www.medworm.com/rss/comments.php?id=728715 Tue, 22 May 2007 02:46:11 +0100 728715